Introduction
============

Gastric cancer (GC) is the most common digestive system tumor and still remains the main cause of human death in developing countries.[@b1-ott-11-001] GC can be divided into early GC and advanced GC according to the degree of malignancy and invasion depth. However, despite advanced diagnosis and treatment have been made in GC in recent years, the survival of GC still remains poor.[@b2-ott-11-001] Systemic chemotherapy is the primary treatment for advanced GC, but there exists a problem of chemotherapy resistance. As is known, tumor--node--metastasis (TNM) stage and patients' age are the most important prognostic factors for GC.[@b3-ott-11-001] However, patients with similar TNM stage and patients' age still show different prognoses in GC. Therefore, identification of genetic biomarkers could be helpful in designing individualized therapy, postoperational treatment, and follow-up strategies.

The DNA repair systems play an important role in repairing the damage to DNA induced by endogenous and/or exogenous factors such as therapeutic agents. Nucleotide excision repair (NER) is a key DNA repair mechanism that can influence gene--gene rearrangement, translocation, and amplification. Previous study reported that the alternation of NER capacity could play a pivotal role in the clinical outcomes of GC patients.[@b4-ott-11-001] The excision repair cross-complementation group 1 (*ERCC1*) enzyme is an essential factor involved in DNA damage repair. It has been reported that *ERCC1* genetic variation can be a predictive marker for prognostic and response to chemotherapy for patients with non-small cell lung cancer (NSCLC), colorectal cancer, and osteosarcoma, and a series of meta-analyses have been performed.[@b5-ott-11-001]--[@b9-ott-11-001] Yamada et al's study showed that low *ERCC1* expression was a significant independent favorable prognostic factor in patients with advanced GC who were receiving first-line chemotherapy regardless of the treatment regimen in JCOG9912. High *ERCC1* expression confers cisplatin resistance and reconstitutes the cell's ability to remove cisplatin from cellular DNA in an animal model.[@b10-ott-11-001]

In recent years, a number of studies have investigated the roles of *ERCC1* gene rs3212986 A/C polymorphisms in the development of GC; however, the results were inconsistent. Here, we conducted a meta-analysis to explore whether rs3212986 A/C polymorphisms in *ERCC1* are predictor factors for the chemotherapy response, as well as the clinical outcome of patients with GC.

Methods
=======

Data sources and searching
--------------------------

We searched the PubMed, Embase, and Web of Science for eligible studies assessing the association of *ERCC1* polymorphisms and response to chemotherapy or overall survival time (last search updated to July 28, 2017). The search terms were "gastric cancer" in combination with "*ERCC1*" in combination with "rs3212986 polymorphism". There was no restriction on time period, sample size, population, language, or type of report in order to minimize potential publication bias.

Inclusion and exclusion criteria
--------------------------------

Studies included in this meta-analysis had to meet the following criteria: 1) case--control studies, 2) studies investigating the association between *ERCC1* gene polymorphisms and response to chemotherapy or survival time, and 3) sufficient data available to calculate an odds ratio (OR) with 95% CI.

The exclusion criteria of the meta-analysis were as follows: 1) case--control studies not focusing on the correlation between *ERCC1* rs3212986 polymorphisms and response to chemotherapy or survival time; 2) availability of insufficient original data for data extraction; and 3) meta-analyses, letters, reviews, and editorial articles. If more than one study was published by the same author using the same patient population, the study with the largest size of samples was included.

Data extraction
---------------

The data of eligible studies were extracted in duplicate by two investigators independently (WT and HW). The following information was recorded: name of first author, year of publication, ethnicity, number of cases and controls, chemotherapeutic drugs, outcomes, and genotype method. Ethnicity was simply categorized as Chinese. Discrepancies were resolved by consensus and by consulting the third author.

Quality assessment
------------------

The quality of the studies was modified from previous meta-analyses and independently assessed by two authors ([Table 1](#t1-ott-11-001){ref-type="table"}).[@b11-ott-11-001],[@b12-ott-11-001] Quality scores ranged from 0 points (worst) to 13 points (best). Studies scoring \<9 points were classified as low quality, and those scoring ≥9 points were classified as high quality.

Statistical analyses
--------------------

Crude ORs with their corresponding 95% CIs were used to assess the strength of association between *ERCC1* polymorphisms and response to chemotherapy or survival time. The Hardy--Weinberg equilibrium (HWE) in the control group was also assessed, and a *P*\<0.05 was considered as significant disequilibrium. This meta-analysis was performed using the RevMan5.2 software. *I*^2^ statistic test was used to examine the heterogeneity. If *I*^2^\>50%, it was considered with severe heterogeneity and the random-effects model would be applied, otherwise fixed-effects model was applied. The potential publication bias was assessed by using a "funnel plot" and Begg's test. A *P*-value of \<0.05 was considered as statistically significant.

Results
=======

Study characteristics
---------------------

A flowchart of the process of study selection is shown in [Figure 1](#f1-ott-11-001){ref-type="fig"}. Based on the inclusion and exclusion criteria, a total of 10 articles were included in the meta-analysis after full-text review. The main characteristics of included studies are presented in [Table 2](#t2-ott-11-001){ref-type="table"}.[@b13-ott-11-001]--[@b22-ott-11-001] The distribution of genotypes in the control groups of all studies was in agreement with HWE except three.[@b18-ott-11-001],[@b20-ott-11-001],[@b21-ott-11-001] A total of 10 studies were performed in Chinese populations. Most studies used the World Health Organization criteria (Miller et al[@b23-ott-11-001]) as the assess criteria while only Bai's study assessed using Response Evaluation Criteria in Solid Tumors (RECIST). In all studies, GC patients who showed complete response (CR) or partial response (PR) to chemotherapy were considered as response to chemotherapy, while patients who showed stable disease (SD) or progressive disease (PD) were considered as nonresponse to chemotherapy.

Association between *ERCC1* gene rs3212986 A/C polymorphisms and response to chemotherapy in GC
-----------------------------------------------------------------------------------------------

Great efforts have been made to identify the molecular predictive markers of chemotherapy sensitivity. In the overall analysis, we did not find any significant association between the *ERCC1* rs3212986 A/C polymorphisms and response to chemotherapy in GC under three comparison models ([Figure 2](#f2-ott-11-001){ref-type="fig"}, AA + CA versus CC, OR 0.95, *P*=0.80; AA versus CA, OR 0.85, *P*=0.55; AA versus CC, OR 0.74, *P*=0.47).

Association between *ERCC1* gene rs3212986 A/C polymorphism and overall survival of GC
--------------------------------------------------------------------------------------

In the overall analysis, we did not find any significant association between the *ERCC1* rs3212986 polymorphisms and overall survival of GC in comparison models ([Figure 3](#f3-ott-11-001){ref-type="fig"}, AA + CA versus CC, OR 1.09, *P*=0.52; AA versus CA, OR 1.05, *P*=0.85; AA versus CC, OR 1.43, *P*=0.23).

Publication bias
----------------

Begg's test was used to assess the publication bias ([Figures 4](#f4-ott-11-001){ref-type="fig"} and [5](#f5-ott-11-001){ref-type="fig"}). The heterogeneity was significantly observed in some comparison models, which might have resulted from differences in ethnicity, country, and genotype methods, so the random-effects model was used. For other polymorphism models, no significant publication bias was observed. This result showed that this meta-analysis was meaningful and the conclusion of this meta-analysis had high credibility.

Discussion
==========

Patients with GC always show individualized response to platinum-based chemotherapy, which may result from hereditary factors by increasing the cell activity of biotransformation, the accumulation of intracellular, and the weakened capacity of DNA repairing.[@b24-ott-11-001]

In recent years, a number of studies have investigated the roles of *ERCC1* gene rs3212986 polymorphisms and serving as potential biomarkers for prognosis in GC. However, the results were inconsistent.

In this study, we described the meta-analysis findings of associations between *ERCC1* gene rs3212986 and treatment outcomes of GC patients receiving chemotherapy. Our study identified that there was no significant association between the *ERCC1* rs3212986 A/C polymorphism and response to chemotherapy in GC. This was inconsistent with the conclusion of some previous studies. Zheng et al[@b13-ott-11-001] have reported that the AA genotype of *ERCC1* rs3212986 was associated with lower rates of complete remission and partial remission following chemotherapy in GC patients. Similarly, Bai et al[@b16-ott-11-001] discovered that patients carrying the GT and TT genotypes of rs3212986 showed a significantly poorer response to chemotherapy than did those carrying the GG genotype. In contrast to them, Zhong et al's[@b17-ott-11-001] research showed no significant association between *ERCC1* rs3212986 polymorphism and GC, which was consistent with our conclusions. Considering the reason, this may result from the complicated and multistep process and NER pathway factors might play an important role in functioning jointly to alter clinical outcome of GC. We further identified *ERCC1* gene rs3212986 polymorphism and treatment outcomes of chemotherapy in GC. We did not find any significant association between the *ERCC1* rs3212986 A/C polymorphisms and overall survival of GC. This was inconsistent with the results of abovementioned studies and the main reasons might be the differences in studies populations, study design, and sample size as well as by chance. To confirm or refute this result, well-designed studies with larger sample sizes and more ethnic groups are suggested performing to validate our conclusion.

Several limitations should not be ignored when interpreting the results. First, all eligible studies were from Chinese populations and our results were limited to this population. Therefore, more studies containing the full range of possible ethnic differences are needed to avoid the bias. Second, we had insufficient data to evaluate such interactions for the independent role of *ERCC1* rs3212986 polymorphisms in GC in this study. Third, we did not perform subgroup analysis by sex, age, or different stages of cancer with limited data in primary studies. Last but not least, publication bias may have occurred due to only published studies included in this study. As a result, further biological and functional evidence is needed to confirm the genetic effects of *ERCC1* rs3212986 A/C polymorphisms on GC.

Conclusion
==========

This meta-analysis indicated that the *ERCC1* rs3212986 A/C polymorphism was not associated with response to chemo-therapy or overall time of GC in Chinese populations. This result should be interpreted cautiously. To confirm or refute this result, well-designed studies with larger sample sizes and more ethnic groups should be further performed to validate.
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###### 

Forest plot for *ERCC1* gene rs3212986 polymorphism and response to chemotherapy in gastric cancer.

**Notes:** (**A**) AA + CA versus CC. (**B**) AA versus CA. (**C**) AA versus CC.

**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.
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###### 

Forest plot for *ERCC1* gene rs3212986 polymorphism and OS in gastric cancer.

**Notes:** (**A**) AA + CA versus CC. (**B**) AA versus CA. (**C**) AA versus CC.

**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel; OS, overall survival.
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![Begg's funnel plot for *ERCC1* gene rs3212986 polymorphism and response to chemotherapy in gastric cancer.\
**Notes:** (**A**) AA + CA versus CC. (**B**) AA versus CA. (**C**) AA versus CC.\
**Abbreviations:** OR, odds ratio; SE, standard error.](ott-11-001Fig4){#f4-ott-11-001}

![Begg's funnel plot for *ERCC1* gene rs3212986 polymorphism and OS in gastric cancer.\
**Notes:** (**A**) AA + CA versus CC. (**B**) AA versus CA. (**C**) AA versus CC.\
**Abbreviations:** OR, odds ratio; OS, overall survival; SE, standard error.](ott-11-001Fig5){#f5-ott-11-001}

###### 

Scale for quality assessment

  Criteria                                                    Score
  ----------------------------------------------------------- -------
  Source of cases                                             
   Selected from population or cancer registry                3
   Selected from hospital                                     2
   Selected from pathology archives but without description   1
   Not described                                              0
  Source of controls                                          
   Population based                                           3
   Blood donors or volunteers                                 2
   Hospital based                                             2
   Not described                                              0
  Genotyping examination                                      
   Genotyping done under "blind" conditions                   2
   Unblinded or not mentioned                                 1
  Hardy--Weinberg equilibrium                                 
   Hardy--Weinberg equilibrium in control group               2
   Hardy--Weinberg disequilibrium in control group            1
  Total sample size                                           
   \>500                                                      3
   \>200 but \<500                                            2
   \<200                                                      1

###### 

Characteristics of the 10 eligible studies included in the meta-analysis

  First author                   Year   Ethnicity   Sample size, number   Chemotherapeutic drugs   Genotyping method               HWE in control                Quality scores                                       
  ------------------------------ ------ ----------- --------------------- ------------------------ ------------------------------- ----------------------------- ---------------------------------------------------- ----
  Zheng et al[@b13-ott-11-001]   2016   Chinese     225                   225                      Platinum based                  PCR-RFLP                      0.98                                                 10
  Mo et al[@b14-ott-11-001]      2015   Chinese     228                   228                      Platinum based                  PCR-RFLP                      0.78                                                 10
  Yu et al[@b15-ott-11-001]      2015   Chinese     346                   346                      5-Fluorouracil                  Sequenom MassARRAY platform   --                                                   10
  Bai et al[@b16-ott-11-001]     2015   Chinese     270                   270                      Platinum based                  Sequenom MassARRAY platform   0.47                                                 10
  Zhong et al[@b17-ott-11-001]   2015   Chinese     263                   253                      Folfox                          PCR                           0.0003[\*](#tfn1a-ott-11-001){ref-type="table-fn"}   9
  Ding et al[@b18-ott-11-001]    2015   Chinese     380                   380                      Platinum based                  PCR-RFLP                      --                                                   
  Xue et al[@b19-ott-11-001]     2015   Chinese     410                   410                      Folfox                          PCR-RFLP                      0.111                                                10
  Yu et al[@b20-ott-11-001]      2015   Chinese     228                   228                      Platinum based                  PCR-RFLP                      0.002[\*](#tfn1a-ott-11-001){ref-type="table-fn"}    9
  Liu et al[@b21-ott-11-001]     2014   Chinese     231                   231                      5-Fluorouracil                  PCR                           0.006[\*](#tfn1a-ott-11-001){ref-type="table-fn"}    9
  Li et al[@b22-ott-11-001]      2014   Chinese     236                   236                      5-Fluorouracil and paclitaxel   PCR                           0.7887                                               10

**Notes:** --, means unclear.

*P*\<0.05.

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.
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